iCeutica Appoints Jyrki Mattila, M.D., as Chief Business Officer

iCeutica Appoints Jyrki Mattila, M.D., as Chief Business Officer

PHILADELPHIA. (October 16, 2013) -- iCeutica, Inc., a company creating branded medicines that provide meaningful clinical benefits to patients, physicians and payers, today announced that Jyrki Mattila, M.D., Ph.D., has joined the company as Chief Business Officer. Dr. Mattila brings over 25 years of business development and management experience to iCeutica and has negotiated and closed over 50 business agreements, including in- and out-licensing, co-marketing, collaboration and product acquisition arrangements. 

Prior to joining iCeutica, Dr. Mattila served as President and CEO of LZ Therapeutics, Inc., where he helped to raise  Series A financing and worked to license exclusive global rights to LZT-1000 for Parkinson’s disease and other neurological conditions. Prior to this position, he was Executive Vice President of Business Development, Product Development and Technical Operations at Auxilium Pharmaceutical, Inc. While at Auxilium, Dr. Mattila helped to significantly grow the company through negotiating licensing agreements, including XIAFLEX® for Dupuytren’s contracture and Peyronie’s disease. Dr. Mattila previously served in a series of positions with increasing seniority at Orion Corporation, including as President of Orion Pharma, where under his leadership several innovative products were developed and commercialized in global markets.

He received his M.D. and Ph.D. in Pharmacology from the University of Helsinki Medical School and an M.B.A. from the Helsinki School of Economics. In addition, Dr. Mattila completed his post-doctoral research fellowship at the University of Kansas Medical Center. 

“Jyrki will be instrumental in driving new collaboration opportunities for iCeutica,” said Osagie Imasogie, Chairman of iCeutica’s Board of Directors and Senior Managing Partner of Phoenix IP Ventures. “iCeutica’s pipeline programs are in areas of significant commercial and medical opportunities that offer the potential to transform currently marketed drugs and novel compounds into new branded medicines.”

Dr. Mattila added, “iCeutica has validated its technology and corporate strategy with the success of its clinical-stage pipeline and partnered programs in pain and inflammation. I look forward to translating iCeutica’s scientific accomplishments across many additional therapeutic areas, including oncology and respiratory disease, into successful industry collaborations.”

Dr. Mattila will attend the BIO-Europe Annual International Partnering Conference, held in Vienna, Austria from November 4-6, to discuss collaboration opportunities with interested companies. 

About iCeutica

iCeutica creates branded medicines by combining our proprietary SoluMatrix™ technology with deep scientific expertise and commercial insights. Our pipeline products provide meaningful clinical benefits for patients and have clearly defined pathways to regulatory and commercial success. We rapidly drive products to market with pharmaceutical partners and by creating new opportunities in focused therapeutic areas.

About Phoenix IP Ventures

A fully-integrated Private Equity and Venture Capital Fund which specializes in life sciences, principally in the pharmaceutical sector, the Firm acquires intellectual property protected assets 

that meet its criteria for value maximization. Phoenix IP Ventures works in collaboration with major players in the financial community to scale its own proprietary investments in transactions identified and managed by the Firm.

Media Contacts

Douglas MacDougall or Jennifer Conrad, MacDougall Biomedical Communications, 781.235.3060

Lisa Gray, Phoenix IP Ventures, 267.765.3233